ARS Pharmaceuticals (SPRY) Total Liabilities (2020 - 2026)

ARS Pharmaceuticals has reported Total Liabilities for 7 years, with the latest figure at $226.3 million in Q1 2026.

• Quarterly Total Liabilities rose 130.07% year-over-year to $226.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.3 million (up 130.07% YoY) and the FY2025 annual result came in at $213.4 million, up 126.16% from the prior year.
• Total Liabilities improved to $226.3 million in Q1 2026 per SPRY's latest filing, from $213.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $226.3 million in Q1 2026 and troughed at $2.4 million in Q4 2023.
• A 5-year average of $63.9 million and a median of $15.2 million in 2022 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities plunged 80.47% in 2022, then soared 3786.12% in 2024.
• Over 5 years, Total Liabilities stood at $8.5 million in 2022, then tumbled by 71.6% to $2.4 million in 2023, then jumped by 3786.12% to $94.4 million in 2024, then soared by 126.16% to $213.4 million in 2025, then rose by 6.03% to $226.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $226.3 million, $213.4 million, and $225.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.